Learning pointsLong-lasting excessive intake of methylephedrine, even through over-the-counter (OTC) paediatric cough syrups, has a potential to cause heart failure.A detailed medical review about the intake of habitual drugs, including OTC, is needed to identify the causes of heart failure.

Introduction
============

Ephedrine is a sympathomimetic drug that stimulates α and β receptors in sympathetic nerve terminals. Reportedly, this drug has adverse effects on the cardiovascular system[@ytaa095-B1] and can cause vasospasm,[@ytaa095-B2] ischaemic stroke,[@ytaa095-B3] and myocardial dysfunction.[@ytaa095-B4]^,^[@ytaa095-B5]

Methylephedrine is another sympathomimetic drug and is considered to be safer than ephedrine, especially when administered at the predetermined dose. Therefore, methylephedrine is often contained in various over-the-counter (OTC) drugs for cold, including paediatric cough syrups, with only few cases of adverse cardiovascular events reported to date.[@ytaa095-B6] Here, we describe a case of heart failure that resulted from the habitual intake of methylephedrine-containing paediatric cough syrup in an adult man who had used the medication for sleep disorders due to night shift work.

Timeline
========

  Time                              Events
  --------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  About 20 years ago                Patient started habitual use of methylephedrine-containing paediatric over-the-counter cough syrup
  Two weeks prior to presentation   Heart failure symptoms with worsening dyspnoea and anorexia developed
  Emergency room admission          Blood pressure and heart rate were 146/98 mmHg and heart rate was 104 b.p.m., respectivelyDecompensated heart failure with reduced left ventricular ejection fraction (EF) of 25%B-type natriuretic peptide was elevated to 1092 ng/LDiscontinuation of the cough syrup after hospitalizationTreatment with low-dose dobutamine (2 μg/kg/min) and furosemide was started
  Day 2                             Enalapril and spironolactone started
  Day 4                             Cardiac rehabilitation initiated
  Day 5                             Carvedilol started
  Day 8                             Right-sided heart catheterization revealed 'wet and cold' profile
  Day 12                            Cardiac magnetic resonance imaging demonstrated diffuse hypokinesis with mid-wall late gadolinium enhancement
  Five weeks                        Discharged homeMedication with 5 mg/day enalapril, 20 mg/day carvedilol, and 25 mg/day spironolactone
  Four months                       New York Class Association Class II. EF was 50%

Case presentation
=================

A 52-year-old man presented at our hospital with worsening dyspnoea and anorexia for 2 weeks. A detailed medical interview revealed that he was a night shift worker and that he had been habitually taking 3--4 bottles (90--120 mL) of methylephedrine-containing paediatric OTC cough syrup daily for 20 years. The syrup contained methylephedrine (40 mg), acetaminophen (450 mg), caffeine (50 mg), chlorpheniramine (5 mg), and dihydrocodeine (16 mg) per bottle. The recommended dose of the syrup was 7.5 mL/day for paediatric use.

On admission, the patient's blood pressure was 146/98 mmHg and heart rate was 104 b.p.m. His chest X-ray revealed pulmonary congestion and electrocardiogram showed sinus tachycardia with left-axis deviation. Echocardiography demonstrated diffuse hypokinesis of the left ventricle with a reduced ejection fraction (EF) of 25% and an increased left ventricular (LV) end-diastolic diameter at 67 mm (*[Figure 1A](#ytaa095-F1){ref-type="fig"}* and [Supplementary material online](#sup1){ref-type="supplementary-material"}, *Videos S1--S3*). Laboratory examination revealed elevated B-type natriuretic peptide \[BNP, 1092 ng/L (normal range: \<18.6 ng/L)\] and liver enzyme levels, which suggested liver congestion. The cough syrup was immediately discontinued after hospitalization. Although his vital signs were relatively stable, we diagnosed his status as decompensated heart failure and low-dose dobutamine infusion was started for low cardiac output symptoms. Even after treatment with low-dose dobutamine and furosemide in intensive care unit, right-heart catheterization demonstrated a 'wet and cold' profile, with a pulmonary capillary wedge pressure of 22 mmHg, mean pulmonary artery pressure of 29 mmHg, and cardiac index of 1.89 L/min/m^2^. Although the patient's coronary angiography revealed normal coronary arteries, his left ventriculography revealed severe diffuse hypokinesis with mild mitral regurgitation (*[Figure 2A and B](#ytaa095-F2){ref-type="fig"}* and [Supplementary material online](#sup1){ref-type="supplementary-material"}, *Video S4*). Pathological examination by right ventricular endomyocardial biopsy revealed cardiomyocyte hypertrophy with moderate interstitial and replacement fibrosis and absence of secondary cardiomyopathies and myocarditis (*[Figure 3A and B](#ytaa095-F3){ref-type="fig"}*). In addition, cardiac magnetic resonance imaging revealed diffuse hypokinesis with mid-wall late gadolinium enhancement, which suggested fibrosis (*[Figure 4](#ytaa095-F4){ref-type="fig"}*).

![(*A*) On admission, echocardiography with M-mode showed diffuse hypokinesis of the left ventricle, and the left ventricular end-diastolic diameter was enlarged at 67 mm. (*B*) Four months after discharge, the ejection fraction was improved to 50%, and left ventricular reverse remodelling was achieved.](ytaa095f1){#ytaa095-F1}

![Left ventriculogram of the patient during (*A*) diastole and (*B*) systole showed severe diffuse hypokinesis.](ytaa095f2){#ytaa095-F2}

![Pathological examination with (*A*) haematoxylin and eosin staining and (*B*) Masson's trichrome staining showed cardiomyocyte hypertrophy with moderate interstitial and replacement fibrosis.](ytaa095f3){#ytaa095-F3}

![Cardiac magnetic resonance imaging showed mid-wall late gadolinium enhancement, which suggested fibrosis.](ytaa095f4){#ytaa095-F4}

Discontinuation of ingesting the cough syrup and optimal medical treatment (OMT) with an angiotensin-converting enzyme inhibitor and a β blocker improved the heart failure symptoms to New York Class Association Class II at 4 months after discharge. The patient's EF was also improved to 50%, and LV reverse remodelling was achieved (*[Figure 1B](#ytaa095-F1){ref-type="fig"}* and [Supplementary material online](#sup1){ref-type="supplementary-material"}, *Videos S5--S7*). In addition, his BNP level decreased and was within the normal range (\<5.8 ng/L).

Discussion
==========

Ephedrine-containing 'ephedra' is widely known as a weight-reducing substance and is used for enhancing exercise capacity. However, it reportedly has a potential to cause adverse cardiac events. The adrenergic effects of ephedrine can induce coronary spasm or shorten the refractory periods in the myocardium. Because several patients who used supplements containing ephedra have reported arrhythmia,[@ytaa095-B7] stroke,[@ytaa095-B3] or myocardial infarction,[@ytaa095-B8] its use was restricted by US Food and Drug Administration. Methylephedrine also has adrenergic effects; however, its effects on the central nervous system and blood pressure are milder than those of ephedrine. Adrenergic effects, especially the β2 adrenoreceptor-stimulating effect, are antitussive in nature. Therefore, methylephedrine is commonly used in cough medicines, including OTC paediatric cough syrups. In the present study, the patient had been habitually taking OTC paediatric cough syrup as a revitalizer for a long time. Even considering body size, the patient had been taking obvious high-dose methylephedrine-containing paediatric cough syrup. We decided the cough syrup was related to heart failure or LV dysfunction, and it was discontinued after hospitalization. In general, hospitalized patients with heart failure experience a reduction in their body weight during the hospitalization period. Although the body weight of the patient in the present study reduced during the decongestion process within the first few days, it increased by 1.2 kg during hospitalization and after decongestion. Therefore, we concluded that the methylephedrine-induced weight loss was reversed and the body weight increased, although the patient was hospitalized for heart failure.

There are a few case reports on ephedrine-induced cardiac dysfunction;[@ytaa095-B4]^,^[@ytaa095-B5] however, the relationship between ephedrine and cardiac dysfunction has not been fully elucidated. The possible underlining mechanisms of ephedrine-induced cardiac dysfunction include myocardial injury due to elevated levels of catecholamine or free radicals.[@ytaa095-B5] In the present study, endomyocardial biopsy revealed cardiomyocyte hypertrophy with moderate interstitial and replacement fibrosis, which is consistent with the findings of myocardial injury caused by continuous catecholamine stimulation. A few animal studies have demonstrated that ephedrine cardiotoxicity was enhanced by the addition of caffeine. Nyska *et al*.[@ytaa095-B9] have suggested that myocardial ischaemia followed by myofibre necrosis was induced more intensively by the combined exposure of ephedrine and caffeine. Therefore, the pathological changes in the myocardium may be caused not only by the methylephedrine but also by the caffeine present in the cough syrup.

Fortunately, the patient's LV systolic dysfunction was reversible, and his heart failure symptoms improved after discontinuation of the cough syrup and OMT. However, the long-lasting excessive intake of methylephedrine must be considered, even through OTC paediatric cough syrups, as a potential cause of LV dysfunction. A detailed medical review about the intake of habitual drugs, including OTC medications, is needed to identify the cause of heart failure or LV dysfunction.
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